Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia , a deadly type of cancer , some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse.

http://www.news-medical.net/news/20121210/Targeting-RAD52-protein-can-block-the-process-by-which-leukemia-stem-cells-repair-themselves.aspx